Ally Financial Inc. Purchases 3,000 Shares of Danaher Corporation $DHR

Ally Financial Inc. raised its position in shares of Danaher Corporation (NYSE:DHR) by 9.1% in the fourth quarter, Holdings Channel reports. The fund owned 36,000 shares of the conglomerate’s stock after buying an additional 3,000 shares during the quarter. Danaher comprises approximately 1.0% of Ally Financial Inc.’s investment portfolio, making the stock its 18th biggest holding. Ally Financial Inc.’s holdings in Danaher were worth $8,241,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in DHR. JPL Wealth Management LLC bought a new stake in shares of Danaher in the third quarter valued at about $25,000. Elevated Capital Advisors LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $26,000. WFA of San Diego LLC bought a new stake in shares of Danaher in the second quarter valued at about $26,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Danaher in the third quarter valued at about $27,000. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $27,000. Institutional investors own 79.05% of the company’s stock.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Danaher Stock Performance

NYSE:DHR opened at $179.95 on Friday. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $127.37 billion, a PE ratio of 34.81, a price-to-earnings-growth ratio of 2.40 and a beta of 0.81. The firm has a 50-day moving average price of $180.93 and a 200 day moving average price of $204.78.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the business posted $1.88 earnings per share. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. Research analysts anticipate that Danaher Corporation will post 8.45 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, June 26th. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. Danaher’s dividend payout ratio (DPR) is presently 30.95%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada assumed coverage on shares of Danaher in a research note on Thursday, May 14th. They issued an “outperform” rating and a $200.00 target price for the company. Rothschild & Co Redburn set a $205.00 target price on shares of Danaher in a research note on Friday, April 17th. Robert W. Baird reduced their target price on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, HSBC reduced their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $233.61.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.